Advances in dendritic cell-based vaccines for HIV

Current Medicinal Chemistry

Volumn 18, Issue 26, 2011, Pages 3987-3994

  Patham, B ^a   Simmons, G L ^a   Subramanya, S ^a  

^a Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

HIV 1; Immunotherapy; Innate immunity; RNA interference (RNAi); Targeted delivery

Indexed keywords

DENDRITIC CELL VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MESSENGER RNA; POL PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR AGONIST; VIRUS ENVELOPE PROTEIN;

ANTIGEN PRESENTATION; CELLULAR IMMUNITY; DRUG FORMULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOTHERAPY; NONHUMAN; REVIEW;

ANIMALS; DENDRITIC CELLS; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; IMMUNOTHERAPY; MICE;

EID: 80052211592     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796957194     Document Type: Review

References (146)

1. Palucka, K.; Banchereau, J.; Mellman, I., Designing vaccines based on biology of human dendritic cell subsets. Immunity 33, (4), 464-78.
2. Mellman, I.; Turley, S. J.; Steinman, R. M., Antigen processing for amateurs and professionals. Trends Cell Biol 1998, 8, (6), 231-7. (Pubitemid 28243205)
3. Steinman, R. M., Dendritic cells: understanding immunogenicity. Eur J Immunol 2007, 37 Suppl 1, S53-60. (Pubitemid 350131268)
4. Villadangos, J. A.; Schnorrer, P., Intrinsic and cooperative antigenpresenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 2007, 7, (7), 543-55. (Pubitemid 46987783)
5. Naik, S. H., Demystifying the development of dendritic cell subtypes, a little. Immunol Cell Biol 2008, 86, (5), 439-52. (Pubitemid 351948216)
6. Merad, M.; Manz, M. G., Dendritic cell homeostasis. Blood 2009, 113, (15), 3418-27.
7. Heath, W. R.; Carbone, F. R., Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 2009, 10, (12), 1237-44.
8. Valladeau, J.; Saeland, S., Cutaneous dendritic cells. Semin Immunol 2005, 17, (4), 273-83. (Pubitemid 40984021)
9. Klechevsky, E.; Morita, R.; Liu, M.; Cao, Y.; Coquery, S.; Thompson-Snipes, L.; Briere, F.; Chaussabel, D.; Zurawski, G.; Palucka, A. K.; Reiter, Y.; Banchereau, J.; Ueno, H., Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008, 29, (3), 497-510.
10. Oh, S.; Perera, L. P.; Burke, D. S.; Waldmann, T. A.; Berzofsky, J. A., IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci U S A 2004, 101, (42), 15154-9. (Pubitemid 39391734)
11. Fazilleau, N.; Mark, L.; McHeyzer-Williams, L. J.; McHeyzer-Williams, M. G., Follicular helper T cells: lineage and location. Immunity 2009, 30, (3), 324-35.
12. Dzionek, A.; Fuchs, A.; Schmidt, P.; Cremer, S.; Zysk, M.; Miltenyi, S.; Buck, D. W.; Schmitz, J., BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000, 165, (11), 6037-46.
13. Siegal, F. P.; Kadowaki, N.; Shodell, M.; Fitzgerald-Bocarsly, P. A.; Shah, K.; Ho, S.; Antonenko, S.; Liu, Y. J., The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284, (5421), 1835-7.
14. Cao, W.; Liu, Y. J., Innate immune functions of plasmacytoid dendritic cells. Curr Opin Immunol 2007, 19, (1), 24-30. (Pubitemid 46073695)
15. Cao, W.; Rosen, D. B.; Ito, T.; Bover, L.; Bao, M.; Watanabe, G.; Yao, Z.; Zhang, L.; Lanier, L. L.; Liu, Y. J., Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J Exp Med 2006, 203, (6), 1399-405. (Pubitemid 43877601)
16. Matsui, T.; Connolly, J. E.; Michnevitz, M.; Chaussabel, D.; Yu, C. I.; Glaser, C.; Tindle, S.; Pypaert, M.; Freitas, H.; Piqueras, B.; Banchereau, J.; Palucka, A. K., CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009, 182, (11), 6815-23.
17. Di Pucchio, T.; Chatterjee, B.; Smed-Sorensen, A.; Clayton, S.; Palazzo, A.; Montes, M.; Xue, Y.; Mellman, I.; Banchereau, J.; Connolly, J. E., Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 2008, 9, (5), 551-7. (Pubitemid 351560524)
18. Poulin, L. F.; Salio, M.; Griessinger, E.; Anjos-Afonso, F.; Craciun, L.; Chen, J. L.; Keller, A. M.; Joffre, O.; Zelenay, S.; Nye, E.; Le Moine, A.; Faure, F.; Donckier, V.; Sancho, D.; Cerundolo, V.; Bonnet, D.; Reis e Sousa, C., Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 207, (6), 1261-71.
19. Jongbloed, S. L.; Kassianos, A. J.; McDonald, K. J.; Clark, G. J.; Ju, X.; Angel, C. E.; Chen, C. J.; Dunbar, P. R.; Wadley, R. B.; Jeet, V.; Vulink, A. J.; Hart, D. N.; Radford, K. J., Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 207, (6), 1247-60.
20. Yoneyama, H.; Matsuno, K.; Toda, E.; Nishiwaki, T.; Matsuo, N.; Nakano, A.; Narumi, S.; Lu, B.; Gerard, C.; Ishikawa, S.; Matsushima, K., Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med 2005, 202, (3), 425-35. (Pubitemid 41126960)
21. Luft, T.; Pang, K. C.; Thomas, E.; Hertzog, P.; Hart, D. N.; Trapani, J.; Cebon, J., Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998, 161, (4), 1947-53. (Pubitemid 28387618)
22. Nagai, T.; Devergne, O.; Mueller, T. F.; Perkins, D. L.; van Seventer, J. M.; van Seventer, G. A., Timing of IFN-beta exposure during human dendritic cell maturation and naive Th cell stimulation has contrasting effects on Th1 subset generation: a role for IFN-beta-mediated regulation of IL-12 family cytokines and IL-18 in naive Th cell differentiation. J Immunol 2003, 171, (10), 5233-43. (Pubitemid 37432808)
23. Fonteneau, J. F.; Larsson, M.; Beignon, A. S.; McKenna, K.; Dasilva, I.; Amara, A.; Liu, Y. J.; Lifson, J. D.; Littman, D. R.; Bhardwaj, N., Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol 2004, 78, (10), 5223-32. (Pubitemid 38581474)
24. Dalod, M.; Hamilton, T.; Salomon, R.; Salazar-Mather, T. P.; Henry, S. C.; Hamilton, J. D.; Biron, C. A., Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. J Exp Med 2003, 197, (7), 885-98. (Pubitemid 36437865)
25. Banchereau, J.; Pascual, V.; Palucka, A. K., Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004, 20, (5), 539-50. (Pubitemid 38638124)
26. Macatonia, S. E.; Hosken, N. A.; Litton, M.; Vieira, P.; Hsieh, C. S.; Culpepper, J. A.; Wysocka, M.; Trinchieri, G.; Murphy, K. M.; O'Garra, A., Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 1995, 154, (10), 5071-9.
27. Weaver, C. T.; Hatton, R. D.; Mangan, P. R.; Harrington, L. E., IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007, 25, 821-52. (Pubitemid 46697925)
28. Kastelein, R. A.; Hunter, C. A.; Cua, D. J., Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007, 25, 221-42. (Pubitemid 46697908)
29. Seliger, B.; Marincola, F. M.; Ferrone, S.; Abken, H., The complex role of B7 molecules in tumor immunology. Trends Mol Med 2008, 14, (12), 550-9.
30. Flies, D. B.; Chen, L., The new B7s: playing a pivotal role in tumor immunity. J Immunother 2007, 30, (3), 251-60. (Pubitemid 46586641)
31. Allison, J. P.; Krummel, M. F., The Yin and Yang of T cell costimulation. Science 1995, 270, (5238), 932-3.
32. Ito, T.; Yang, M.; Wang, Y. H.; Lande, R.; Gregorio, J.; Perng, O. A.; Qin, X. F.; Liu, Y. J.; Gilliet, M., Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007, 204, (1), 105-15. (Pubitemid 46148761)
33. Hutloff, A.; Dittrich, A. M.; Beier, K. C.; Eljaschewitsch, B.; Kraft, R.; Anagnostopoulos, I.; Kroczek, R. A., ICOS is an inducible T-cell costimulator structurally and functionally related to CD28. Nature 1999, 397, (6716), 263-6.
34. Ito, M.; Minamiya, Y.; Kawai, H.; Saito, S.; Saito, H.; Nakagawa, T.; Imai, K.; Hirokawa, M.; Ogawa, J., Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node. J Immunol 2006, 176, (9), 5637-43.
35. Steinman, R. M.; Hawiger, D.; Nussenzweig, M. C., Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21, 685-711. (Pubitemid 37174545)
36. Shakhar, G.; Lindquist, R. L.; Skokos, D.; Dudziak, D.; Huang, J. H.; Nussenzweig, M. C.; Dustin, M. L., Stable T cell-dendritic cell interactions precede the development of both tolerance and immunity in vivo. Nat Immunol 2005, 6, (7), 707-14. (Pubitemid 41716744)
37. Shen, L.; Evel-Kabler, K.; Strube, R.; Chen, S. Y., Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific antitumor immunity. Nat Biotechnol 2004, 22, (12), 1546-53. (Pubitemid 40039457)
38. Evel-Kabler, K.; Song, X. T.; Aldrich, M.; Huang, X. F.; Chen, S. Y., SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest 2006, 116, (1), 90-100. (Pubitemid 43121794)
39. Hanada, T.; Yoshida, H.; Kato, S.; Tanaka, K.; Masutani, K.; Tsukada, J.; Nomura, Y.; Mimata, H.; Kubo, M.; Yoshimura, A., Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003, 19, (3), 437-50. (Pubitemid 37153419)
40. Subramanya, S.; Armant, M.; Salkowitz, J. R.; Nyakeriga, A. M.; Haridas, V.; Hasan, M.; Bansal, A.; Goepfert, P. A.; Wynn, K. K.; Ladell, K.; Price, D. A.; N, M.; Kan-Mitchell, J.; Shankar, P., Enhanced induction of HIVspecific cytotoxic T lymphocytes by dendritic cell-targeted delivery of SOCS-1 siRNA. Mol Ther 18, (11), 2028-37.
41. Song, X. T.; Evel-Kabler, K.; Rollins, L.; Aldrich, M.; Gao, F.; Huang, X. F.; Chen, S. Y., An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med 2006, 3, (1), e11.
42. Rutella, S.; Danese, S.; Leone, G., Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006, 108, (5), 1435-40. (Pubitemid 44316106)
43. Filippi, C. M.; von Herrath, M. G., IL-10 and the resolution of infections. J Pathol 2008, 214, (2), 224-30. (Pubitemid 351160159)
44. Liu, G.; Ng, H.; Akasaki, Y.; Yuan, X.; Ehtesham, M.; Yin, D.; Black, K. L.; Yu, J. S., Small interference RNA modulation of IL-10 in human monocytederived dendritic cells enhances the Th1 response. Eur J Immunol 2004, 34, (6), 1680-7. (Pubitemid 39256050)
45. Lee, E. G.; Boone, D. L.; Chai, S.; Libby, S. L.; Chien, M.; Lodolce, J. P.; Ma, A., Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000, 289, (5488), 2350-4.
46. Oshima, N.; Ishihara, S.; Rumi, M. A.; Aziz, M. M.; Mishima, Y.; Kadota, C.; Moriyama, I.; Ishimura, N.; Amano, Y.; Kinoshita, Y., A20 is an early responding negative regulator of Toll-like receptor 5 signalling in intestinal epithelial cells during inflammation. Clin Exp Immunol 159, (2), 185-98.
47. Breckpot, K.; Aerts-Toegaert, C.; Heirman, C.; Peeters, U.; Beyaert, R.; Aerts, J. L.; Thielemans, K., Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. J Immunol 2009, 182, (2), 860-70.
48. Ha, S. J.; Mueller, S. N.; Wherry, E. J.; Barber, D. L.; Aubert, R. D.; Sharpe, A. H.; Freeman, G. J.; Ahmed, R., Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med 2008, 205, (3), 543-55. (Pubitemid 351439302)
49. Henson, S. M.; Macaulay, R.; Kiani-Alikhan, S.; Akbar, A. N., The use of the inhibitory receptors for modulating the immune responses. Curr Pharm Des 2008, 14, (26), 2643-50.
50. Trautmann, L.; Janbazian, L.; Chomont, N.; Said, E. A.; Gimmig, S.; Bessette, B.; Boulassel, M. R.; Delwart, E.; Sepulveda, H.; Balderas, R. S.; Routy, J. P.; Haddad, E. K.; Sekaly, R. P., Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006, 12, (10), 1198-202. (Pubitemid 44527357)
51. Day, C. L.; Kaufmann, D. E.; Kiepiela, P.; Brown, J. A.; Moodley, E. S.; Reddy, S.; Mackey, E. W.; Miller, J. D.; Leslie, A. J.; DePierres, C.; Mncube, Z.; Duraiswamy, J.; Zhu, B.; Eichbaum, Q.; Altfeld, M.; Wherry, E. J.; Coovadia, H. M.; Goulder, P. J.; Klenerman, P.; Ahmed, R.; Freeman, G. J.; Walker, B. D., PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443, (7109), 350-4. (Pubitemid 44435155)
52. Petrovas, C.; Casazza, J. P.; Brenchley, J. M.; Price, D. A.; Gostick, E.; Adams, W. C.; Precopio, M. L.; Schacker, T.; Roederer, M.; Douek, D. C.; Koup, R. A., PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006, 203, (10), 2281-92. (Pubitemid 44498363)
53. Menke, J.; Lucas, J. A.; Zeller, G. C.; Keir, M. E.; Huang, X. R.; Tsuboi, N.; Mayadas, T. N.; Lan, H. Y.; Sharpe, A. H.; Kelley, V. R., Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles. J Immunol 2007, 179, (11), 7466-77.
54. Habicht, A.; Kewalaramani, R.; Vu, M. D.; Demirci, G.; Blazar, B. R.; Sayegh, M. H.; Li, X. C., Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo. Am J Transplant 2007, 7, (12), 2683-92. (Pubitemid 350045774)
55. Vicari, A. P.; Vanbervliet, B.; Massacrier, C.; Chiodoni, C.; Vaure, C.; Ait-Yahia, S.; Dercamp, C.; Matsos, F.; Reynard, O.; Taverne, C.; Merle, P.; Colombo, M. P.; O'Garra, A.; Trinchieri, G.; Caux, C., In vivo manipulation of dendritic cell migration and activation to elicit antitumour immunity. Novartis Found Symp 2004, 256, 241-54; discussion 254-69.
56. Frumento, G.; Piazza, T.; Di Carlo, E.; Ferrini, S., Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 2006, 6, (3), 233-7.
57. Evel-Kabler, K.; Chen, S. Y., Inhibition of antigen-presentation attenuators to augment vaccines. Curr Opin Mol Ther 2006, 8, (1), 24-30. (Pubitemid 43230897)
58. Lu, W.; Andrieu, J. M., In vitro human immunodeficiency virus eradication by autologous CD8(+) T cells expanded with inactivated-virus-pulsed dendritic cells. J Virol 2001, 75, (19), 8949-56. (Pubitemid 32851899)
59. Lu, W.; Arraes, L. C.; Ferreira, W. T.; Andrieu, J. M., Therapeutic dendriticcell vaccine for chronic HIV-1 infection. Nat Med 2004, 10, (12), 1359-65. (Pubitemid 40022718)
60. Garcia, F.; Lejeune, M.; Climent, N.; Gil, C.; Alcami, J.; Morente, V.; Alos, L.; Ruiz, A.; Setoain, J.; Fumero, E.; Castro, P.; Lopez, A.; Cruceta, A.; Piera, C.; Florence, E.; Pereira, A.; Libois, A.; Gonzalez, N.; Guila, M.; Caballero, M.; Lomena, F.; Joseph, J.; Miro, J. M.; Pumarola, T.; Plana, M.; Gatell, J. M.; Gallart, T., Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005, 191, (10), 1680-5. (Pubitemid 40656756)
61. Larsson, M.; Fonteneau, J. F.; Lirvall, M.; Haslett, P.; Lifson, J. D.; Bhardwaj, N., Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus. AIDS 2002, 16, (10), 1319-29. (Pubitemid 34722063)
62. Zhao, X. Q.; Huang, X. L.; Gupta, P.; Borowski, L.; Fan, Z.; Watkins, S. C.; Thomas, E. K.; Rinaldo, C. R., Jr., Induction of anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) and CD4(+) T-cell reactivity by dendritic cells loaded with HIV-1 X4-infected apoptotic cells. J Virol 2002, 76, (6), 3007-14. (Pubitemid 34184885)
63. Maranon, C.; Desoutter, J. F.; Hoeffel, G.; Cohen, W.; Hanau, D.; Hosmalin, A., Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes. Proc Natl Acad Sci U S A 2004, 101, (16), 6092-7. (Pubitemid 38520533)
64. Albert, M. L., Death-defying immunity: do apoptotic cells influence antigen processing and presentation? Nat Rev Immunol 2004, 4, (3), 223-31. (Pubitemid 38339088)
65. Connolly, N. C.; Whiteside, T. L.; Wilson, C.; Kondragunta, V.; Rinaldo, C. R.; Riddler, S. A., Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008, 15, (2), 284-92. (Pubitemid 352025534)
66. Bansal, A.; Carlson, J.; Yan, J.; Akinsiku, O. T.; Schaefer, M.; Sabbaj, S.; Bet, A.; Levy, D. N.; Heath, S.; Tang, J.; Kaslow, R. A.; Walker, B. D.; Ndung'u, T.; Goulder, P. J.; Heckerman, D.; Hunter, E.; Goepfert, P. A., CD8 T cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense transcription. J Exp Med 207, (1), 51-9.
67. Wiley, R. D.; Gummuluru, S., Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. Proc Natl Acad Sci U S A 2006, 103, (3), 738-43. (Pubitemid 43153095)
68. Gilboa, E.; Vieweg, J., Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 2004, 199, 251-63. (Pubitemid 38744521)
69. Weissman, D.; Ni, H.; Scales, D.; Dude, A.; Capodici, J.; McGibney, K.; Abdool, A.; Isaacs, S. N.; Cannon, G.; Kariko, K., HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J Immunol 2000, 165, (8), 4710-7.
70. Kavanagh, D. G.; Kaufmann, D. E.; Sunderji, S.; Frahm, N.; Le Gall, S.; Boczkowski, D.; Rosenberg, E. S.; Stone, D. R.; Johnston, M. N.; Wagner, B. S.; Zaman, M. T.; Brander, C.; Gilboa, E.; Walker, B. D.; Bhardwaj, N., Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm-or lysosome-targeted Nef. Blood 2006, 107, (5), 1963-9. (Pubitemid 43289378)
71. Cisco, R. M.; Abdel-Wahab, Z.; Dannull, J.; Nair, S.; Tyler, D. S.; Gilboa, E.; Vieweg, J.; Daaka, Y.; Pruitt, S. K., Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive tolllike receptor 4. J Immunol 2004, 172, (11), 7162-8. (Pubitemid 38669160)
72. Bontkes, H. J.; Kramer, D.; Ruizendaal, J. J.; Kueter, E. W.; van Tendeloo, V. F.; Meijer, C. J.; Hooijberg, E., Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther 2007, 14, (4), 366-75. (Pubitemid 46231930)
73. Tcherepanova, I. Y.; Adams, M. D.; Feng, X.; Hinohara, A.; Horvatinovich, J.; Calderhead, D.; Healey, D.; Nicolette, C. A., Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol Biol 2008, 9, 90.
74. Bonehill, A.; Tuyaerts, S.; Van Nuffel, A. M.; Heirman, C.; Bos, T. J.; Fostier, K.; Neyns, B.; Thielemans, K., Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 2008, 16, (6), 1170-80. (Pubitemid 351737084)
75. Dannull, J.; Nair, S.; Su, Z.; Boczkowski, D.; DeBeck, C.; Yang, B.; Gilboa, E.; Vieweg, J., Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 2005, 105, (8), 3206-13.
76. Grunebach, F.; Kayser, K.; Weck, M. M.; Muller, M. R.; Appel, S.; Brossart, P., Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes. Cancer Gene Ther 2005, 12, (9), 749-56. (Pubitemid 41208614)
77. Lenz, P.; Bacot, S. M.; Frazier-Jessen, M. R.; Feldman, G. M., Nucleoporation of dendritic cells: efficient gene transfer by electroporation into human monocyte-derived dendritic cells. FEBS Lett 2003, 538, (1-3), 149-54. (Pubitemid 36287441)
78. Van Gulck, E. R.; Vanham, G.; Heyndrickx, L.; Coppens, S.; Vereecken, K.; Atkinson, D.; Florence, E.; Kint, I.; Berneman, Z. N.; Van Tendeloo, V., Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals. J Virol 2008, 82, (7), 3561-73. (Pubitemid 351429932)
79. Tcherepanova, I.; Harris, J.; Starr, A.; Cleveland, J.; Ketteringham, H.; Calderhead, D.; Horvatinovich, J.; Healey, D.; Nicolette, C. A., Multiplex RT-PCR amplification of HIV genes to create a completely autologous DCbased immunotherapy for the treatment of HIV infection. PLoS One 2008, 3, (1), e1489.
80. Tan, X.; Wan, Y., Enhanced protein expression by internal ribosomal entry site-driven mRNA translation as a novel approach for in vitro loading of dendritic cells with antigens. Hum Immunol 2008, 69, (1), 32-40.
81. Mignone, F.; Gissi, C.; Liuni, S.; Pesole, G., Untranslated regions of mRNAs. Genome Biol 2002, 3, (3), REVIEWS0004.
82. Mockey, M.; Goncalves, C.; Dupuy, F. P.; Lemoine, F. M.; Pichon, C.; Midoux, P., mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level. Biochem Biophys Res Commun 2006, 340, (4), 1062-8. (Pubitemid 43083386)
83. Milano, F.; van Baal, J. W.; Rygiel, A. M.; Bergman, J. J.; Van Deventer, S. J.; Kapsenberg, M. L.; Peppelenbosch, M. P.; Krishnadath, K. K., An improved protocol for generation of immuno-potent dendritic cells through direct electroporation of CD14+ monocytes. J Immunol Methods 2007, 321, (1-2), 94-106. (Pubitemid 46441201)
84. Michiels, A.; Breckpot, K.; Corthals, J.; Tuyaerts, S.; Bonehill, A.; Heirman, C.; Thielemans, K.; Aerts, J. L., Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther 2006, 13, (13), 1027-36. (Pubitemid 43905855)
85. Kariko, K.; Ni, H.; Capodici, J.; Lamphier, M.; Weissman, D., mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 2004, 279, (13), 12542-50. (Pubitemid 38445825)
86. Barouch, D. H.; Nabel, G. J., Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005, 16, (2), 149-56. (Pubitemid 40344207)
87. Buchbinder, S. P.; Mehrotra, D. V.; Duerr, A.; Fitzgerald, D. W.; Mogg, R.; Li, D.; Gilbert, P. B.; Lama, J. R.; Marmor, M.; Del Rio, C.; McElrath, M. J.; Casimiro, D. R.; Gottesdiener, K. M.; Chodakewitz, J. A.; Corey, L.; Robertson, M. N., Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-ofconcept trial. Lancet 2008, 372, (9653), 1881-93.
88. Robb, M. L., Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 2008, 372, (9653), 1857-8.
89. McElrath, M. J.; De Rosa, S. C.; Moodie, Z.; Dubey, S.; Kierstead, L.; Janes, H.; Defawe, O. D.; Carter, D. K.; Hural, J.; Akondy, R.; Buchbinder, S. P.; Robertson, M. N.; Mehrotra, D. V.; Self, S. G.; Corey, L.; Shiver, J. W.; Casimiro, D. R., HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372, (9653), 1894-905.
90. Girard, M. P.; Bansal, G. P., HIV/AIDS vaccines: a need for new concepts? Int Rev Immunol 2008, 27, (6), 447-71.
91. Patterson, S.; Papagatsias, T.; Benlahrech, A., Use of adenovirus in vaccines for HIV. Handb Exp Pharmacol 2009, (188), 275-93.
92. Yang, L.; Yang, H.; Rideout, K.; Cho, T.; Joo, K. I.; Ziegler, L.; Elliot, A.; Walls, A.; Yu, D.; Baltimore, D.; Wang, P., Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008, 26, (3), 326-34. (Pubitemid 351355129)
93. Strayer, D. S.; Akkina, R.; Bunnell, B. A.; Dropulic, B.; Planelles, V.; Pomerantz, R. J.; Rossi, J. J.; Zaia, J. A., Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther 2005, 11, (6), 823-42. (Pubitemid 40724101)
94. Creagh, E. M.; O'Neill, L. A., TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006, 27, (8), 352-7. (Pubitemid 44038661)
95. Pulendran, B., Modulating vaccine responses with dendritic cells and Tolllike receptors. Immunol Rev 2004, 199, 227-50. (Pubitemid 38736775)
96. Pulendran, B.; Palucka, K.; Banchereau, J., Sensing pathogens and tuning immune responses. Science 2001, 293, (5528), 253-6. (Pubitemid 32694733)
97. Pulendran, B., Variegation of the immune response with dendritic cells and pathogen recognition receptors. J Immunol 2005, 174, (5), 2457-65. (Pubitemid 40279654)
98. Pichlmair, A.; Reis e Sousa, C., Innate recognition of viruses. Immunity 2007, 27, (3), 370-83. (Pubitemid 47418682)
99. van Duin, D.; Medzhitov, R.; Shaw, A. C., Triggering TLR signaling in vaccination. Trends Immunol 2006, 27, (1), 49-55. (Pubitemid 43083564)
100. Yarovinsky, F.; Kanzler, H.; Hieny, S.; Coffman, R. L.; Sher, A., Toll-like receptor recognition regulates immunodominance in an antimicrobial CD4+ T cell response. Immunity 2006, 25, (4), 655-64. (Pubitemid 44529033)
101. Heit, A.; Schmitz, F.; O'Keeffe, M.; Staib, C.; Busch, D. H.; Wagner, H.; Huster, K. M., Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J Immunol 2005, 174, (7), 4373-80. (Pubitemid 40396020)
102. Wille-Reece, U.; Flynn, B. J.; Lore, K.; Koup, R. A.; Kedl, R. M.; Mattapallil, J. J.; Weiss, W. R.; Roederer, M.; Seder, R. A., HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci U S A 2005, 102, (42), 15190-4. (Pubitemid 41513357)
103. Wille-Reece, U.; Wu, C. Y.; Flynn, B. J.; Kedl, R. M.; Seder, R. A., Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol 2005, 174, (12), 7676-83. (Pubitemid 40806272)
104. Schlosser, E.; Mueller, M.; Fischer, S.; Basta, S.; Busch, D. H.; Gander, B.; Groettrup, M., TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008, 26, (13), 1626-37.
105. Datta, S. K.; Redecke, V.; Prilliman, K. R.; Takabayashi, K.; Corr, M.; Tallant, T.; DiDonato, J.; Dziarski, R.; Akira, S.; Schoenberger, S. P.; Raz, E., A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 2003, 170, (8), 4102-10. (Pubitemid 36428173)
106. Le Bon, A.; Etchart, N.; Rossmann, C.; Ashton, M.; Hou, S.; Gewert, D.; Borrow, P.; Tough, D. F., Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003, 4, (10), 1009-15. (Pubitemid 37265922)
107. Meyer-Wentrup, F.; Benitez-Ribas, D.; Tacken, P. J.; Punt, C. J.; Figdor, C. G.; de Vries, I. J.; Adema, G. J., Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood 2008, 111, (8), 4245-53.
108. Steinman, R. M.; Banchereau, J., Taking dendritic cells into medicine. Nature 2007, 449, (7161), 419-26. (Pubitemid 47509552)
109. Rinaldo, C. R., Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med 2009, 265, (1), 138-58.
110. Tacken, P. J.; Torensma, R.; Figdor, C. G., Targeting antigens to dendritic cells in vivo. Immunobiology 2006, 211, (6-8), 599-608.
111. Johnson, T. S.; Mahnke, K.; Storn, V.; Schonfeld, K.; Ring, S.; Nettelbeck, D. M.; Haisma, H. J.; Le Gall, F.; Kontermann, R. E.; Enk, A. H., Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule. Clin Cancer Res 2008, 14, (24), 8169-77.
112. Bozzacco, L.; Trumpfheller, C.; Siegal, F. P.; Mehandru, S.; Markowitz, M.; Carrington, M.; Nussenzweig, M. C.; Piperno, A. G.; Steinman, R. M., DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A 2007, 104, (4), 1289-94. (Pubitemid 46183997)
113. Nchinda, G.; Amadu, D.; Trumpfheller, C.; Mizenina, O.; Uberla, K.; Steinman, R. M., Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells. Proc Natl Acad Sci U S A 107, (9), 4281-6.
114. Kretz-Rommel, A.; Qin, F.; Dakappagari, N.; Torensma, R.; Faas, S.; Wu, D.; Bowdish, K. S., In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother 2007, 30, (7), 715-26. (Pubitemid 47480755)
115. Dakappagari, N.; Maruyama, T.; Renshaw, M.; Tacken, P.; Figdor, C.; Torensma, R.; Wild, M. A.; Wu, D.; Bowdish, K.; Kretz-Rommel, A., Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses. J Immunol 2006, 176, (1), 426-40. (Pubitemid 43023289)
116. Adams, E. W.; Ratner, D. M.; Seeberger, P. H.; Hacohen, N., Carbohydratemediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells. Chembiochem 2008, 9, (2), 294-303. (Pubitemid 351196798)
117. Romani, N.; Thurnher, M.; Idoyaga, J.; Steinman, R. M.; Flacher, V., Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol Cell Biol 88, (4), 424-30.
118. Nayak, B. P.; Sailaja, G.; Jabbar, A. M., Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4. J Virol 2003, 77, (20), 10850-61. (Pubitemid 37204278)
119. Bozzacco, L.; Trumpfheller, C.; Huang, Y.; Longhi, M. P.; Shimeliovich, I.; Schauer, J. D.; Park, C. G.; Steinman, R. M., HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC. Eur J Immunol 40, (1), 36-46.
120. Wang, B.; Kuroiwa, J. M.; He, L. Z.; Charalambous, A.; Keler, T.; Steinman, R. M., The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Ann N Y Acad Sci 2009, 1174, 6-17.
121. Kraal, G.; Samsom, J. N.; Mebius, R. E., The importance of regional lymph nodes for mucosal tolerance. Immunol Rev 2006, 213, 119-30. (Pubitemid 44401497)
122. Pack, M.; Trumpfheller, C.; Thomas, D.; Park, C. G.; Granelli-Piperno, A.; Munz, C.; Steinman, R. M., DEC-205/CD205+ dendritic cells are abundant in the white pulp of the human spleen, including the border region between the red and white pulp. Immunology 2008, 123, (3), 438-46. (Pubitemid 351171195)
123. Badiee, A.; Davies, N.; McDonald, K.; Radford, K.; Michiue, H.; Hart, D.; Kato, M., Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine 2007, 25, (25), 4757-66. (Pubitemid 46818617)
124. Trumpfheller, C.; Caskey, M.; Nchinda, G.; Longhi, M. P.; Mizenina, O.; Huang, Y.; Schlesinger, S. J.; Colonna, M.; Steinman, R. M., The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc Natl Acad Sci U S A 2008, 105, (7), 2574-9. (Pubitemid 351520555)
125. Nchinda, G.; Kuroiwa, J.; Oks, M.; Trumpfheller, C.; Park, C. G.; Huang, Y.; Hannaman, D.; Schlesinger, S. J.; Mizenina, O.; Nussenzweig, M. C.; Uberla, K.; Steinman, R. M., The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 2008, 118, (4), 1427-36. (Pubitemid 351500436)
126. Gurer, C.; Strowig, T.; Brilot, F.; Pack, M.; Trumpfheller, C.; Arrey, F.; Park, C. G.; Steinman, R. M.; Munz, C., Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 2008, 112, (4), 1231-9.
127. Curiel, T. J.; Morris, C.; Brumlik, M.; Landry, S. J.; Finstad, K.; Nelson, A.; Joshi, V.; Hawkins, C.; Alarez, X.; Lackner, A.; Mohamadzadeh, M., Peptides identified through phage display direct immunogenic antigen to dendritic cells. J Immunol 2004, 172, (12), 7425-31. (Pubitemid 38747604)
128. Subramanya, S.; Kim, S. S.; Abraham, S.; Yao, J.; Kumar, M.; Kumar, P.; Haridas, V.; Lee, S. K.; Shultz, L. D.; Greiner, D.; N, M.; Shankar, P.,
129. Brody, E. N.; Gold, L., Aptamers as therapeutic and diagnostic agents. J Biotechnol 2000, 74, (1), 5-13.
130. Famulok, M.; Mayer, G., Aptamers as tools in molecular biology and immunology. Curr Top Microbiol Immunol 1999, 243, 123-36. (Pubitemid 29296960)
131. Dong, H.; Strome, S. E.; Salomao, D. R.; Tamura, H.; Hirano, F.; Flies, D. B.; Roche, P. C.; Lu, J.; Zhu, G.; Tamada, K.; Lennon, V. A.; Celis, E.; Chen, L., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8, (8), 793-800.
132. Chen, L., Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004, 4, (5), 336-47. (Pubitemid 38649276)
133. Santulli-Marotto, S.; Nair, S. K.; Rusconi, C.; Sullenger, B.; Gilboa, E., Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res 2003, 63, (21), 7483-9. (Pubitemid 37413492)
134. McNamara, J. O.; Kolonias, D.; Pastor, F.; Mittler, R. S.; Chen, L.; Giangrande, P. H.; Sullenger, B.; Gilboa, E., Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J Clin Invest 2008, 118, (1), 376-86.
135. Dollins, C. M.; Nair, S.; Boczkowski, D.; Lee, J.; Layzer, J. M.; Gilboa, E.; Sullenger, B. A., Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol 2008, 15, (7), 675-82. (Pubitemid 351957907)
136. Xu, H.; Wang, X.; Pahar, B.; Moroney-Rasmussen, T.; Alvarez, X.; Lackner, A. A.; Veazey, R. S., Increased B7-H1 Expression on Dendritic Cells Correlates with Programmed Death 1 Expression on T Cells in Simian Immunodeficiency Virus-Infected Macaques and May Contribute to T Cell Dysfunction and Disease Progression. J Immunol.
137. Triebel, F., LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 2003, 24, (12), 619-22. (Pubitemid 37485908)
138. Hobo, W.; Maas, F.; Adisty, N.; de Witte, T.; Schaap, N.; van der Voort, R.; Dolstra, H., siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood.
139. Kran, A. M.; Sorensen, B.; Sommerfelt, M. A.; Nyhus, J.; Baksaas, I.; Kvale, D., Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells. AIDS 2006, 20, (4), 627-30. (Pubitemid 43731611)
140. Lisziewicz, J.; Kelly, L.; Lori, F., Topical DermaVir vaccine targeting dendritic cells. Curr Drug Deliv 2006, 3, (1), 83-8.
141. Lori, F.; Calarota, S. A.; Lisziewicz, J., Nanochemistry-based immunotherapy for HIV-1. Curr Med Chem 2007, 14, (18), 1911-9. (Pubitemid 47209102)
142. Calarota, S. A.; Dai, A.; Trocio, J. N.; Weiner, D. B.; Lori, F.; Lisziewicz, J., IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine. Vaccine 2008, 26, (40), 5188-95.
143. Gandhi, R. T.; O'Neill, D.; Bosch, R. J.; Chan, E. S.; Bucy, R. P.; Shopis, J.; Baglyos, L.; Adams, E.; Fox, L.; Purdue, L.; Marshak, A.; Flynn, T.; Masih, R.; Schock, B.; Mildvan, D.; Schlesinger, S. J.; Marovich, M. A.; Bhardwaj, N.; Jacobson, J. M., A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009, 27, (43), 6088-94.
144. Bachem, A.; Guttler, S.; Hartung, E.; Ebstein, F.; Schaefer, M.; Tannert, A.; Salama, A.; Movassaghi, K.; Opitz, C.; Mages, H. W.; Henn, V.; Kloetzel, P. M.; Gurka, S.; Kroczek, R. A., Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 207, (6), 1273-81.
145. Querec, T.; Bennouna, S.; Alkan, S.; Laouar, Y.; Gorden, K.; Flavell, R.; Akira, S.; Ahmed, R.; Pulendran, B., Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006, 203, (2), 413-24. (Pubitemid 43290850)
146. Gaucher, D.; Therrien, R.; Kettaf, N.; Angermann, B. R.; Boucher, G.; Filali-Mouhim, A.; Moser, J. M.; Mehta, R. S.; Drake, D. R., 3rd; Castro, E.; Akondy, R.; Rinfret, A.; Yassine-Diab, B.; Said, E. A.; Chouikh, Y.; Cameron, M. J.; Clum, R.; Kelvin, D.; Somogyi, R.; Greller, L. D.; Balderas, R. S.; Wilkinson, P.; Pantaleo, G.; Tartaglia, J.; Haddad, E. K.; Sekaly, R. P., Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008, 205, (13), 3119-31.